Phuturdex › Diseases › Thrombocythemia, Essential
Drugs in development · updated 30 October 2026
Thrombocythemia, Essential: drugs in development
As of 30 October 2026 there are 35 active clinical trials (recruiting or ongoing, phases I–III) on 43 drugs for thrombocythemia, Essential. 15 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BomedemstatIMG-7289 | III | 5 | NCT06079879 |
| INCA033989 | III | 3 | NCT07623200 |
| Iadademstat | II | 1 | NCT06661915 |
| JBI-802 | I–II | 1 | NCT07612280 |
| Pevonedistat | I–II | 1 | NCT03862157 |
| STP938 | II | 1 | NCT06786234 |
| VeliparibABT-888 | II | 1 | NCT03289910 |
| DMR-001 | I | 1 | NCT07849231 |
| GLB-001 | I | 1 | NCT06378437 |
| INCA035784 | I | 1 | NCT07008118 |
| INCA036978 | I | 1 | NCT07441694 |
| INCB057643 | I | 1 | NCT04279847 |
| Navitoclax | I | 1 | NCT04041050 |
| Poly ICLCHiltonol | I | 1 | NCT05025488 |
| ZE74-0282-0001 | I | 1 | NCT07527221 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RuxolitinibJakavi, Jakafi Xr® | III | 9 | NCT06079879 |
| Ropeginterferon alfa-2bP1101, Besremi® | III | 3 | NCT04285086 |
| AnagrelideAgrylin®, Anagrelide Viatris (previously Anagrelide Mylan)® | III | 2 | NCT06079879 |
| BusulfanBusulphan, Busulfex® | III | 2 | NCT06079879 |
| Ropeginterferon alfa-2b-njftBesremi® | III | 2 | NCT05481151 |
| AspirinVazalore®, Durlaza® | III | 1 | NCT05198960 |
| HydroxyureaHydroxycarbamide, Hydroxycarbamid | III | 1 | NCT06456346 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 2 | NCT00544115 |
| DecitabineDacogen® | II | 2 | NCT06661915 |
| FludarabineFludara, FLUDARABIN | II | 2 | NCT00544115 |
| MelphalanEvomela®, Hepzato® | II | 2 | NCT00544115 |
| MethotrexateJylamvo®, Reditrex® | II | 2 | NCT00544115 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 2 | NCT00544115 |
| PacritinibVonjo® | II | 2 | NCT04282187 |
| TacrolimusEnvarsus XR, Prograf® | II | 2 | NCT00544115 |
Sorted by most advanced phase and number of active trials. Showing 15 of 28 drugs.
All 43 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Bone marrow disease 14 drugs
- Hematologic Diseases 57 drugs
- Blood coagulation disease 4 drugs
- Hemorrhagic disease 6 drugs
- Thrombocytosis 8 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D013920 “Thrombocythemia, Essential”. Prevalence: Orphanet.